Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of multiple doses of PLX-200 in patients with CLN3 disease.


Clinical Trial Description

This is a phase 3, double-blind, placebo-controlled, dose-titration study to evaluate escalating weight-based dose levels of PLX-200, provided as a solution that contains 15 mg/mL PLX-200 and administered orally using a syringe, as needed, twice daily (BID), 30 minutes before breakfast and dinner. Participants will enter the Titration Period, during which the starting dose of PLX-200 or placebo will be based on patient weight. Each patient's dose will be titrated upward on a weekly basis during the Titration Period, until he or she reaches a maximally tolerated dose (MTD) or the Week 5 dose for their weight category. The patient will then enter the Maintenance Period at the final Titration Period dose for a maximum of 60 weeks. Safety, efficacy, and pharmacokinetics will be assessed periodically. Thereafter, all patients will have the opportunity to receive active treatment in an Open-Label Extension (OLE) for an additional 36 weeks. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04637282
Study type Interventional
Source Polaryx Therapeutics, Inc.
Contact Luis Rojas, MSc, PhD.
Phone 305-510-4820
Email luis.rojas@polaryx.com
Status Not yet recruiting
Phase Phase 3
Start date December 1, 2024
Completion date December 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT01399047 - Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis Phase 2
Recruiting NCT05642221 - Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls